{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:49:08Z","timestamp":1780336148260,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13318-024-00932-1","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T18:38:32Z","timestamp":1738175912000},"page":"139-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leveraging Model-Based Simulations to Optimize Extended Dosing of Leuprolide 6-Month Intramuscular Depot Formulation"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-3500","authenticated-orcid":false,"given":"Li-Feng","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"3","key":"932_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"issue":"5","key":"932_CR2","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.urology.2015.07.034","volume":"86","author":"F Saad","year":"2015","unstructured":"Saad F, Fizazi K. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer. Urology. 2015;86(5):852\u201361. https:\/\/doi.org\/10.1016\/j.urology.2015.07.034.","journal-title":"Urology"},{"key":"932_CR3","unstructured":"FDA. Label of LUPRON DEPOT (leuprolide acetate for depot suspension). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/019732s045,020517s043lbl.pdf. Accessed date: 21 Sep 2024."},{"issue":"5","key":"932_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336. https:\/\/doi.org\/10.1016\/j.eururo.2014.07.010.","journal-title":"Eur Urol"},{"issue":"2","key":"932_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1756287217738985","volume":"10","author":"D Meani","year":"2018","unstructured":"Meani D, Solari\u0107 M, Visap\u00e4\u00e4 H, Ros\u00e9n RM, Janknegt R, So\u010de M. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Ther Adv Urol. 2018;10(2):51\u201363. https:\/\/doi.org\/10.1177\/1756287217738985.","journal-title":"Ther Adv Urol"},{"issue":"4","key":"932_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.eururo.2015.10.007","volume":"69","author":"C Schulman","year":"2016","unstructured":"Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, G\u00f3mez Veiga F, Baskin-Bey E, L\u00f3pez B, Tombal B. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study(ICELAND). Eur Urol. 2016;69(4):720\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2015.10.007.","journal-title":"Eur Urol"},{"issue":"6","key":"932_CR7","first-page":"429","volume":"44","author":"M Ortiz","year":"2015","unstructured":"Ortiz M. Benefits of less frequent injections in advanced prostate cancer. Aust Fam Physician. 2015;44(6):429\u201330.","journal-title":"Aust Fam Physician"},{"issue":"6","key":"932_CR8","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.juro.2007.01.157","volume":"177","author":"AS Pathak","year":"2007","unstructured":"Pathak AS, Pacificar JS, Shapiro CE, Williams SG. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol. 2007;177(6):2132\u20135. https:\/\/doi.org\/10.1016\/j.juro.2007.01.157. (discussion 2135).","journal-title":"J Urol"},{"issue":"9","key":"932_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-015-0251-9","volume":"54","author":"CN Lim","year":"2015","unstructured":"Lim CN, Salem AH. A semi-mechanistic integrated pharmacokinetic\/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. Clin Pharmacokinet. 2015;54(9):963\u201373. https:\/\/doi.org\/10.1007\/s40262-015-0251-9.","journal-title":"Clin Pharmacokinet"},{"key":"932_CR10","unstructured":"FDA. Advanced Prostate Cancer: Developing gonadotropin-releasing hormone analogues guidance for industry 2022. https:\/\/www.fda.gov\/media\/129027\/download. Accessed date: 21 Sep 2024."},{"issue":"1","key":"932_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24\u201338. https:\/\/doi.org\/10.1038\/s41391-018-0079-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"932_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/pcan.2011.50","volume":"15","author":"A Spitz","year":"2012","unstructured":"Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J, Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012;15(1):93\u20139. https:\/\/doi.org\/10.1038\/pcan.2011.50.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/rru.S111475","volume":"8","author":"A Spitz","year":"2016","unstructured":"Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, Gruca D, Norton M. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng\/dL threshold: a retrospective analysis of two Phase III studies. Res Reports Urol. 2016;8:159\u201364. https:\/\/doi.org\/10.2147\/rru.S111475.","journal-title":"Res Reports Urol"},{"issue":"7","key":"932_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/bcp.13577","volume":"84","author":"XS Xu","year":"2018","unstructured":"Xu XS, Yuan M, Zhu H, Yang Y, Wang H, Zhou H, Xu J, Zhang L, Pinheiro J. Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity. Br J Clin Pharmacol. 2018;84(7):1525\u201334. https:\/\/doi.org\/10.1111\/bcp.13577.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"932_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eururo.2023.09.007","volume":"84","author":"B Tombal","year":"2023","unstructured":"Tombal B, Collins S, Morgans AK, Hunsche E, Brown B, Zhu E, Bossi A, Shore N. Impact of Relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study. Eur Urol. 2023;84(6):579\u201387. https:\/\/doi.org\/10.1016\/j.eururo.2023.09.007.","journal-title":"Eur Urol"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","volume":"158","author":"FC Maluf","year":"2021","unstructured":"Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, Bastos DA, C\u00e1rcano FM, Smaletz O, Soares A, Peixoto FA, Gomes AJ, Cruz FM, Franke FA, Herchenhorn D, Dos Santos TM, Fabricio VC, Gidekel R, Werutsky G, de Jesus RG, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer (Oxford, England: 1990). 2021;158:63\u201371. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.032. (Advance online publication).","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"3","key":"932_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clgc.2018.01.005","volume":"16","author":"M Claps","year":"2018","unstructured":"Claps M, Petrelli F, Caffo O, Amoroso V, Roca E, Mosca A, Maines F, Barni S, Berruti A. Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis. Clin Genitourin Cancer. 2018;16(3):165-175.e162. https:\/\/doi.org\/10.1016\/j.clgc.2018.01.005.","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00932-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:15:32Z","timestamp":1741194932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00932-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00932-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"16 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are my personal opinions and not necessarily the recommendations of the Taiwan CDE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"No funding was received.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"I declare that I have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All data was generated from the published model.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"I designed the research, analyzed the data, and wrote the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"This study does not involve human participants, and therefore, a consent to participate declaration is not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate Declaration"}},{"value":"As this study was based solely on computer simulations, no human subjects were involved. Therefore, ethical approval and the adherence to norms or standards such as the Declaration of Helsinki are not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Declaration (Norm or Standard)"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate Declarations"}}]}}